Welcome to LookChem.com Sign In|Join Free

CAS

  • or

856691-93-5

Post Buying Request

856691-93-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

856691-93-5 Usage

General Description

CEP-11981, also known as tert-butyl (E)-4-(2-fluoro-4-hydroxy-5-methoxyphenyl) but-3-enoate, is a chemical compound that belongs to the class of esters. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. CEP-11981 has been found to possess anti-inflammatory and anti-proliferative properties, making it a potential candidate for the development of new medicinal drugs. Its unique molecular structure and functional groups make it a valuable building block for the production of various biologically active compounds. Further research is warranted to explore the full potential and applications of CEP-11981 in the field of drug discovery and development.

Check Digit Verification of cas no

The CAS Registry Mumber 856691-93-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,6,6,9 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 856691-93:
(8*8)+(7*5)+(6*6)+(5*6)+(4*9)+(3*1)+(2*9)+(1*3)=225
225 % 10 = 5
So 856691-93-5 is a valid CAS Registry Number.

856691-93-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name CHEMBL2010872

1.2 Other means of identification

Product number -
Other names UNII-J8AY0Z4CBP

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:856691-93-5 SDS

856691-93-5Downstream Products

856691-93-5Relevant articles and documents

Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-Methylpropyl)-12, 13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4 H -indazolo[5,4-a]pyrrolo[3,4-c] carbazol-4-one (CEP-11981): A novel oncology therapeutic agent

Hudkins, Robert L.,Becknell, Nadine C.,Zulli, Allison L.,Underiner, Ted L.,Angeles, Thelma S.,Aimone, Lisa D.,Albom, Mark S.,Chang, Hong,Miknyoczki, Sheila J.,Hunter, Kathryn,Jones-Bolin, Susan,Zhao, Hugh,Bacon, Edward R.,Mallamo, John P.,Ator, Mark A.,Ruggeri, Bruce A.

, p. 903 - 913 (2012)

A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor growth in a variety of solid and hematopoietic tumors. Given the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapy necessitates inhibition of multiple, complementary, and nonredundant angiogenic targets. 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8- (pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (11b, CEP-11981) is a potent orally active inhibitor of multiple targets (TIE-2, VEGF-R1, 2, and 3, and FGF-R1) having essential and nonredundant roles in tumor angiogenesis and vascular maintenance. Outlined in this article are the design strategy, synthesis, and biochemical and pharmacological profile for 11b, which completed Phase I clinical assessing safety and pharmacokinetics allowing for the initiation of proof of concept studies.

Novel fused pyrrolocarbazoles

-

Page/Page column 61; 97, (2010/02/12)

The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these f

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 856691-93-5